Cargando…

Leflunomide therapy for IgA vasculitis with nephritis in children

BACKGROUND: Henoch-Schönlein purpura (HSP), also called IgA vasculitis, is a systemic vasculitis characterized by deposits of immunoglobulin A in blood vessels. Renal impairment of these patients is the main determinant of prognosis. The optimal treatment of HSP nephritis (HSPN) in children remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Ling, Zhang, Zhou, Du, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424791/
https://www.ncbi.nlm.nih.gov/pubmed/34496826
http://dx.doi.org/10.1186/s12887-021-02866-y
_version_ 1783749729864122368
author Hou, Ling
Zhang, Zhou
Du, Yue
author_facet Hou, Ling
Zhang, Zhou
Du, Yue
author_sort Hou, Ling
collection PubMed
description BACKGROUND: Henoch-Schönlein purpura (HSP), also called IgA vasculitis, is a systemic vasculitis characterized by deposits of immunoglobulin A in blood vessels. Renal impairment of these patients is the main determinant of prognosis. The optimal treatment of HSP nephritis (HSPN) in children remains controversial, but many clinicians administer an immunosuppressive agent with a corticosteroid. A previous study reported that leflunomide (LEF) with a corticosteroid was effective for adult patients with HSPN and nephrotic proteinuria. However, data on this treatment in pediatric patients is limited. METHODS: We described our experience at a single center on the use of LEF in 5 pediatric patients who had IgA vasculitis with proteinuria that was nearly 50 mg/kg (nephrotic range) and remained high despite administration of intravenous steroid, and biopsy-proven nephritis. All patients had class II to IIIb lesions based on the International Study of Kidney Disease in Children (ISKDC). RESULTS: We successfully treated all 5 children who had IgA vasculitis with nephritis using LEF with a corticosteroid. Four patients achieved a complete remission of proteinuria, and 1 patient had significantly reduced proteinuria. The children received LEF for 6 months to 12 months, and none of them had severe adverse events. CONCLUSIONS: To our knowledge, this is the first case series to report successful treatment of pediatric HSPN with LEF in combination with a corticosteroid.
format Online
Article
Text
id pubmed-8424791
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84247912021-09-10 Leflunomide therapy for IgA vasculitis with nephritis in children Hou, Ling Zhang, Zhou Du, Yue BMC Pediatr Research BACKGROUND: Henoch-Schönlein purpura (HSP), also called IgA vasculitis, is a systemic vasculitis characterized by deposits of immunoglobulin A in blood vessels. Renal impairment of these patients is the main determinant of prognosis. The optimal treatment of HSP nephritis (HSPN) in children remains controversial, but many clinicians administer an immunosuppressive agent with a corticosteroid. A previous study reported that leflunomide (LEF) with a corticosteroid was effective for adult patients with HSPN and nephrotic proteinuria. However, data on this treatment in pediatric patients is limited. METHODS: We described our experience at a single center on the use of LEF in 5 pediatric patients who had IgA vasculitis with proteinuria that was nearly 50 mg/kg (nephrotic range) and remained high despite administration of intravenous steroid, and biopsy-proven nephritis. All patients had class II to IIIb lesions based on the International Study of Kidney Disease in Children (ISKDC). RESULTS: We successfully treated all 5 children who had IgA vasculitis with nephritis using LEF with a corticosteroid. Four patients achieved a complete remission of proteinuria, and 1 patient had significantly reduced proteinuria. The children received LEF for 6 months to 12 months, and none of them had severe adverse events. CONCLUSIONS: To our knowledge, this is the first case series to report successful treatment of pediatric HSPN with LEF in combination with a corticosteroid. BioMed Central 2021-09-08 /pmc/articles/PMC8424791/ /pubmed/34496826 http://dx.doi.org/10.1186/s12887-021-02866-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hou, Ling
Zhang, Zhou
Du, Yue
Leflunomide therapy for IgA vasculitis with nephritis in children
title Leflunomide therapy for IgA vasculitis with nephritis in children
title_full Leflunomide therapy for IgA vasculitis with nephritis in children
title_fullStr Leflunomide therapy for IgA vasculitis with nephritis in children
title_full_unstemmed Leflunomide therapy for IgA vasculitis with nephritis in children
title_short Leflunomide therapy for IgA vasculitis with nephritis in children
title_sort leflunomide therapy for iga vasculitis with nephritis in children
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424791/
https://www.ncbi.nlm.nih.gov/pubmed/34496826
http://dx.doi.org/10.1186/s12887-021-02866-y
work_keys_str_mv AT houling leflunomidetherapyforigavasculitiswithnephritisinchildren
AT zhangzhou leflunomidetherapyforigavasculitiswithnephritisinchildren
AT duyue leflunomidetherapyforigavasculitiswithnephritisinchildren